Kolexia
Sedel Frederic Neurologie
Sedel Frederic
Neurologie
Hôpital Pitie Salpetriere
Paris, France
103 Activités
747 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sclérose Sclérose en plaques Maladie de Niemann-Pick de type C Démence de Pick Maladies de Niemann-Pick Sclérose en plaques chronique progressive Encéphalopathies Ataxie Maladies mitochondriales

Collaborateurs

Voir plus
Tourbah Ayman
Tourbah Ayman
Hôpital Raymond-Poincaré, Garches, France
Mochel Fanny
Mochel Fanny
Hôpital Pitie Salpetriere, Paris, France
Degos Bertrand
Degos Bertrand
Hôpital Avicenne, Bobigny, France
Galanaud Damien
Galanaud Damien
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study.
BMC neurology   30 octobre 2023
A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars.
Aesthetic surgery journal. Open forum   23 mars 2023
High Dose Pharmaceutical Grade Biotin (MD1003) Accelerates Differentiation of Murine and Grafted Human Oligodendrocyte Progenitor Cells In Vivo.
International journal of molecular sciences   12 décembre 2022
SPI2: Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Essai Clinique (MedDay)   29 octobre 2020
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Essai Clinique (MedDay)   29 octobre 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Neurology   23 octobre 2020
High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy.
Brain pathology (Zurich, Switzerland)   07 juillet 2020
P149: Axonal Integrity by MRS at Baseline in the SPI2 Ph3 Trial of MD1003 (hdPB): Effect of Sex, Disease Burden, and Progressive MS Type
Multiple sclerosis (Houndmills, Basingstoke, England) Congress 2020   11 mai 2020
P040: Remotely Monitored Ambulatory Activity Correlates With Disability In Progressive MS: Baseline Data From The SPI2 Ph3 Trial Of Md1003 (hdpb Biotin)
Multiple sclerosis (Houndmills, Basingstoke, England) Congress 2020   11 mai 2020
P172: Spinal Cord Area Correlates With Disability And Quality Of Life In Progressive Ms: Baseline Mri Analysis From The Spi2 Ph3 Trial Of Md1003 (hdpb)
Multiple sclerosis (Houndmills, Basingstoke, England) Congress 2020   11 mai 2020